ClinicalTrials.gg
CompletedNCT04595370MIRACLEUpdated Nov 19, 2024Results posted

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

A Phase 2 interventional study of AZD9977 and Dapagliflozin in Heart Failure and Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 156 sites in 22 countries. Open to participants aged 21 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
21 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Enrollment
20th of 59
153 · median 100
Started
2021
with 9 others
Phase 2
9 of 59
4 open now
Registered
17th of 59
by date
Lead sponsor
7 of 59
AstraZeneca

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 20th largest by enrollment, is one of 10 that started in 2021, is one of 9 in phase 2, and was the 17th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 21 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m\^2, with at least 20% of participants with eGFR ≥ 20 to \<30 mL/min/1.73\^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m\^2]).

Read the detailed description

After screening, eligible participants will undergo a run-in period where all participants receive dapagliflozin for up to 7 weeks depending on pre-study use of SGLT2i or not. At the end of the run-in period, eligible participants will be randomly assigned with a 1:1:1:1 ratio to receive once daily administration of one of the following 4 study treatments group for 12 weeks. To ensure blinding, the study treatment will be administered in the form of 3 oral capsules of AZD9977 or placebo and 1 oral tablet or dapagliflozin.

  1. AZD9977 Dose A + dapagliflozin 10 mg
  2. AZD9977 Dose B + dapagliflozin 10 mg
  3. AZD9977 Dose C + dapagliflozin 10 mg
  4. Dapagliflozin 10 mg

Participants will be randomized to one of the above treatment group, according to type 2 diabetes mellitus [T2DM (yes/no)] and eGFR (≥ 20 to \<30 mL/min/1.73\^2; or ≥ 30 to \< 45 mL/min/1.73\^2; or ≥45 mL/min/1.73\^2).

The total duration of participation will be approximately 22 to 24weeks.

03

Conditions studied

  • Heart Failure
  • Chronic Kidney Disease

Keywords

  • Heart Failure
  • Type 2 diabetes mellitus
  • Diabetic kidney disease
  • Chronic kidney disease
  • Mineralocorticoid receptor modulator
  • Sodium-glucose co-transporter-2 inhibitor
  • AZD9977
  • Dapagliflozin
  • Urinary albumin creatinine ratio
04

Who can participate

Ages eligible
21 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are included in the study if any of the following criteria apply:

  • Documented diagnosis of stable symptomatic HF ( class II-III) at screening, and a medical history of typical symptoms and signs of HF in those who are currently receiving loop diuretic treatment
  • \<60% documented by the most recent echocardiogram or cardiac magnetic resonance imaging within the last 12 months prior to screening
  • Stable background treatment for HF, hypertension, diabetes mellitus or renal disease according to guidelines
  • N-terminal-pro-brain natriuretic peptide (NT proBNP) ≥300 pg/mL for participants with sinus rhythm at screening; and NT proBNP ≥600 pg/mL for participants with atrial fibrillation/flutter at screening
  • The ≥30 and ≤60 mL/min/1.73\^2 (by CKD- EPI formula) and UACR ≥30 mg/g (3 mg/mmol) and \<3000 mg/g (300 mg/mmol)
  • less than 40 kg/m\^2
  • Serum/plasma K+ level ≥ 3.5 and \< 5.0 mmol/L within 10 days prior to randomization
  • Serum/ plasma Na+ level within normal reference values within 10 days prior to randomization
  • Systolic blood pressure should be at protocol defined range at randomization (Visit 3), with no change to antihypertensive treatments in previous 3 weeks
  • Male or female of non-
  • All participants must follow protocol defined procedures

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Primary glomerulopathy, vasculitic renal disease, prior dialysis or unstable rapidly progressing renal disease, autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or anti-neutrophil cytoplasm antibody-associated vasculitis
  • Participants with currently decompensated HF requiring hospitalization for optimization of HF treatment and are not on stable HF therapy at the time of enrollment
  • HF due to cardiomyopathies
  • High output HF (e.g., due to hyperthyroidism or Paget's disease)
  • HF due to pericardial disease, congenital heart disease or uncorrected primary cardiac valvular disease or planned cardiac valve repair/replacement
  • Participants with uncontrolled diabetes mellitus ( >10%)
  • Participants with Type 1 diabetes mellitus
  • Intermittent or persistent 2nd or 3rd degree atrioventricular block, sinus node dysfunction with clinically significant bradycardia or sinus pauses, not treated with a pacemaker
  • History of any life-threatening cardiac dysrhythmia or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter
  • Acute coronary syndrome and/or elective/non-elective percutaneous cardiac interventions (within 3 months) prior to randomisation or is planned to undergo any of these procedures during the study
  • Any major cardiovascular (eg, open chest, coronary artery bypass grafting or valvular repair/replacement) or major non-cardiovascular surgery within 3 months prior to randomisation or is planned to undergo any cardiovascular surgery during the study
  • Heart transplantation or left ventricular assist device at any time or if these are planned
  • Kidney or any organ transplantation or if these are planned
  • Medical conditions associated with development of hyperkalaemia (Addison's disease )
  • History or ongoing allergy/, to sodium-glucose co-transporter-2 inhibitor (SGLT2i e.g., dapagliflozin, empagliflozin)
  • Stroke, , carotid surgery, or carotid angioplasty within previous 3 months prior to randomisation
  • Hepatic disease, including hepatitis and/or hepatic impairment ( class A-C), and or alanine transaminase or total should be in protocol defined range at time of screening and/ or within 7 days prior to randomization
  • Participants with newly detected pathological laboratory values or an ongoing disease condition
  • If the participants clinical signs and symptoms consistent with COVID-19, and has been previously hospitalized with COVID-19 infection and did not fully recover their previous health status
  • Previous randomization in the present study
  • Prior medical treatment with an mineralocorticoid receptor antagonist where the medication was taken within 90 days prior to screening
  • Current or prior treatment within 6 months prior to screening with cytotoxic therapy, therapy, or other immunotherapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    AZD9977 Dose A + dapagliflozin 10 mg

    Participants will receive once daily oral dose A of AZD9977 and 10 mg dapagliflozin for 12 weeks.

    Drug: AZD9977 · Drug: Dapagliflozin

  • Experimental
    AZD9977 Dose B + dapagliflozin 10 mg

    Participants will receive once daily oral dose B of AZD9977 and 10 mg dapagliflozin for 12 weeks.

    Drug: AZD9977 · Drug: Dapagliflozin

  • Experimental
    AZD9977 Dose C + dapagliflozin 10 mg

    Participants will receive once daily oral dose C of AZD9977 and 10 mg dapagliflozin for 12 weeks.

    Drug: AZD9977 · Drug: Dapagliflozin

  • Experimental
    Dapagliflozin 10 mg

    Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.

    Drug: Dapagliflozin

Interventions

  • Participants will receive AZD9977 as per the arms they are randomized.

  • Participants will receive dapagliflozin as per the arms they are randomized.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12

    The effect of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone on UACR assessed. Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as 10 x urine albumin (mg per deciliter \[mg/dL\])/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants only descriptive statistics are shown for those two arms without formal comparison.

    Time frame: Baseline (Day 1) to Week 12

Secondary outcomes

  1. Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship

    The dose-response relationship of dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on UACR was assessed. Urine samples were collected for the analysis of UACR. UACR (mg/g) was calculated as 10 x urine albumin (mg/dL)/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants, only descriptive statistics was shown for those two arms without formal comparison.

    Time frame: Baseline (Day 1) to Week 12

  2. Number of Participants With Adverse Events (AEs)

    The safety and tolerability of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo was assessed.

    Time frame: From baseline (Day 1) until Day 113

  3. Change From Baseline in Serum Potassium (K+)

    Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.

    Time frame: Baseline (Day 1) and Week 12

  4. Absolute Value of Serum Potassium Over Time

    Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.

    Time frame: Baseline (Day 1) and Week 12

  5. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed.

    Time frame: Baseline (Day 1) and Week 12

  6. Absolute Value of eGFR Over Time

    Effect of all doses of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed

    Time frame: Baseline (Day 1) to Week 12

07

Results

Posted Nov 19, 2024
Limitations and caveats
Enrolment stopped early because of slow recruitment. Therefore, pre-specified sample size of 500 and planned statistical power were not achieved. Nine subjects were excluded from analysis due to site misconduct and GCP non-compliance.

Participant flow

The study was conducted between 26-January-2021 (first subject first visit) to 22-September-2023 (last subject last visit).

Participant flow — Overall Study
MilestoneAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Started3533367357
Completed3325276296
Not completed289161
Withdrew: Subjects randomised, not treated, protocol deviation100000
Withdrew: Subjects randomised, not treated, withdrawal by subject001000
Withdrew: Adverse event043111
Withdrew: Withdrawal of consent111000
Withdrew: Death010010
Withdrew: Protocol-specified withdrawal criterion met001000
Withdrew: Withdrawal by subject001020
Withdrew: Lost to follow-up000010
Withdrew: Participants discontinued study treatment due to other reasons022010

Outcome measures

PrimaryPercent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12

The effect of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone on UACR assessed. Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as 10 x urine albumin (mg per deciliter \[mg/dL\])/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants only descriptive statistics are shown for those two arms without formal comparison.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12
Percent change from baselineAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12-56.391 (-71.528 to -33.207)-42.085 (-64.174 to -6.376)-58.047 (-73.560 to -33.430)-45.01 (NA to NA)-34.318 (-58.204 to 3.220)230.32 (NA to NA)
Statistical analysis
  • AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg · F-Test · p = 0.3645 · F test statistics: 1.07
SecondaryPercent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship

The dose-response relationship of dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on UACR was assessed. Urine samples were collected for the analysis of UACR. UACR (mg/g) was calculated as 10 x urine albumin (mg/dL)/urine creatinine (g/dL). Change from baseline in UACR at the end of 12 weeks of study treatment was calculated as the average of the UACR values at Week 12 and was analyzed by a mixed-effects model for repeated measures (MMRM). Due to early removal of arms (AZD9977 150 mg monotherapy and Placebo), the study objectives were revised and the MMRM analysis included the 4 remaining arms (AZD9977 15 mg + Dapagliflozin, AZD9977 50 mg + Dapagliflozin, AZD9977 150 mg + Dapagliflozin, and Dapagliflozin 10 mg). Since 2 arms were removed from the study resulting in fewer participants, only descriptive statistics was shown for those two arms without formal comparison.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship
Percent change from baselineAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at 12 Weeks to Assess Dose-Response Relationship-56.391 (-71.528 to -33.207)-42.085 (-64.174 to -6.376)-58.047 (-73.560 to -33.430)-45.01 (NA to NA)-34.318 (-58.204 to 3.220)230.32 (NA to NA)
Statistical analysis
  • AZD9977 15 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.1588 · Percent difference between treatment: -33.606 · 95% CI -62.530 to 17.644
  • AZD9977 50 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.6846 · Percent difference between treatment: -11.826 · 95% CI -52.195 to 62.634
  • AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg · Mixed Models Analysis · p = 0.1398 · Percent difference between treatment: -36.127 · 95% CI -64.850 to 16.066
SecondaryNumber of Participants With Adverse Events (AEs)

The safety and tolerability of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo was assessed.

Time frame:
From baseline (Day 1) until Day 113
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Any AE912185143
Any SAE132042
Any SAE with outcome death020010
Any AE leading to discontinuation of IP043111
Any AE leading to withdrawal from study052010
Any AE leading to dose interruption111031
SecondaryChange From Baseline in Serum Potassium (K+)

Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline in Serum Potassium (K+)
millimoles per liter (mmol/L)AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Change From Baseline in Serum Potassium (K+)0.056 (-0.106 to 0.219)0.003 (-0.184 to 0.190)0.109 (-0.061 to 0.279)0.55 (NA to NA)0.040 (-0.129 to 0.209)0.03 (NA to NA)
SecondaryAbsolute Value of Serum Potassium Over Time

Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on serum K+ was assessed.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · mmol/L
Absolute Value of Serum Potassium Over Time
mmol/LAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Baseline4.60 ± 0.384.44 ± 0.614.46 ± 0.444.50 ± 0.384.60 ± 0.664.50 ± 0.28
Week 124.62 ± 0.504.53 ± 0.434.63 ± 0.435.00 ± 0.614.64 ± 0.404.33 ± 0.32
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR)

Effect of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · mL/min/1.73 m^2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73 m^2AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)-1.432 (-4.305 to 1.441)-1.160 (-4.351 to 2.030)-5.307 (-8.295 to -2.320)-0.923 (NA to NA)-3.498 (-6.528 to -0.469)6.880 (NA to NA)
SecondaryAbsolute Value of eGFR Over Time

Effect of all doses of AZD9977 combined with dapagliflozin 10 mg, AZD9977 monotherapy, dapagliflozin 10 mg monotherapy and placebo on eGFR was assessed

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Mean · mL/min/1.73 m^2
Absolute Value of eGFR Over Time
mL/min/1.73 m^2AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
Baseline41.341 ± 12.90238.586 ± 10.15543.663 ± 16.16836.874 ± 12.62641.895 ± 12.79140.288 ± 15.176
Week 1241.219 ± 15.11239.429 ± 8.99839.063 ± 13.81934.075 ± 21.07137.973 ± 11.57148.920 ± 21.111

Adverse events

Collected over From baseline (Day 1) until Day 113. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9977 15 mg + Dapagliflozin 10 mg0/33 (0%)1/33 (3%)1/33 (3%)
AZD9977 50 mg + Dapagliflozin 10 mg2/31 (6.5%)3/31 (9.7%)4/31 (12.9%)
AZD9977 150 mg + Dapagliflozin 10 mg0/34 (0%)2/34 (5.9%)13/34 (38.2%)
AZD9977 150 mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Dapagliflozin 10 mg1/33 (3%)4/33 (12.1%)7/33 (21.2%)
Placebo0/5 (0%)2/5 (40%)2/5 (40%)
Most frequent serious events
Most frequent serious events
EventAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
COVID-19Infections and infestations0/331/310/340/60/331/5
Cardiac failureCardiac disorders0/331/311/340/60/331/5
Left ventricular failureCardiac disorders0/331/310/340/60/330/5
OsteoarthritisMusculoskeletal and connective tissue disorders0/331/310/340/60/330/5
Cardiac failure congestiveCardiac disorders0/330/310/340/61/330/5
Lower gastrointestinal haemorrhageGastrointestinal disorders0/330/310/340/61/330/5
Peripheral swellingGeneral disorders0/330/310/340/61/330/5
Sudden cardiac deathGeneral disorders0/330/310/340/61/330/5
Hepatic enzyme increasedInvestigations1/330/310/340/60/330/5
Transient ischaemic attackNervous system disorders0/330/311/340/60/330/5
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlacebo
DiarrhoeaGastrointestinal disorders0/330/312/340/60/331/5
SyncopeVascular disorders0/330/311/340/60/331/5
ColitisGastrointestinal disorders0/330/310/340/60/331/5
HyperthyroidismEndocrine disorders0/330/310/340/60/331/5
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/330/310/340/60/331/5
Diabetes mellitusEndocrine disorders0/330/310/340/60/331/5
HyperkalaemiaMetabolism and nutrition disorders0/331/312/341/63/330/5
Chronic kidney diseaseRenal and urinary disorders1/331/312/341/61/330/5
HypotensionVascular disorders0/330/310/341/60/330/5
HeadacheNervous system disorders0/330/310/341/60/330/5

Baseline characteristics

Total 153 participants were randomized but 9 participants were excluded from full analysis set (FAS) due to good clinical practice (GCP) misconduct at site. Hence, 144 participants were included in FAS. FAS included all participants who were randomized and either received or did not receive any study intervention.

Age, Continuous
Age, Continuous(Years)AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlaceboTotal
Mean70.9 ± 7.172.4 ± 8.473.7 ± 8.177.0 ± 8.772.2 ± 9.477.2 ± 5.872.7 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlaceboTotal
Female1158110136
Male2326275234108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9977 15 mg + Dapagliflozin 10 mgAZD9977 50 mg + Dapagliflozin 10 mgAZD9977 150 mg + Dapagliflozin 10 mgAZD9977 150 mgDapagliflozin 10 mgPlaceboTotal
Asian43703017
Black or African American0110215
White3027276284122
08

Study locations

156 sites
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    S. Gate, California 90280, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Homestead, Florida 33032, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Ocala, Florida 34474, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Methuen, Massachusetts 01844, United States
  • Research Site
    Saint Louis, Missouri 63136, United States
  • Research Site
    Bronx, New York 10455, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Houston, Texas 77087, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    San Antonio, Texas 78207, United States
  • Research Site
    Sherman, Texas 75092, United States
  • Research Site
    Webster, Texas 77598, United States
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 1606, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Plovdiv, 4003, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1510, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Veliko Turnovo, 5000, Bulgaria
  • Research Site
    Peterborough, Ontario K9J 0B2, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Pardubice, 532 03, Czechia
  • Research Site
    Praha 2, 120 00, Czechia
  • Research Site
    Praha 5, 158 00, Czechia
  • Research Site
    Uherske Hradiste, 68601, Czechia
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Svendborg, 5700, Denmark
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Frankfurt, 60313, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Balatonfüred, 8230, Hungary
  • Research Site
    Budapest, 1036, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Miskolc, 3530, Hungary
  • Research Site
    Oroshaza, H-5900, Hungary
  • Research Site
    Ahmedabad, 382421, India
  • Research Site
    Chennai, 600081, India
  • Research Site
    Kolkata, 700020, India
  • Research Site
    Pune, 411011, India
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Hamada-shi, 697-8511, Japan
  • Research Site
    Hamamatsu-shi, 430-0929, Japan
  • Research Site
    Hanyu-shi, 348-8505, Japan
  • Research Site
    Itabashi-ku, 173-8610, Japan
  • Research Site
    Kasugai-shi, 487-0016, Japan
  • Research Site
    Kawaguchi, 333-0842, Japan
  • Research Site
    Kishiwada-shi, 596-8522, Japan
  • Research Site
    Kobe-shi, 650-0047, Japan
  • Research Site
    Kobe, 654-0155, Japan
  • Research Site
    Matsudo-Shi, 271-0077, Japan
  • Research Site
    Matsumoto-shi, 390-8621, Japan
  • Research Site
    Ono, 675-1392, Japan
  • Research Site
    Osaka-shi, 530-0001, Japan
  • Research Site
    Sapporo-shi, 006-0811, Japan
  • Research Site
    Sayama, 350-1305, Japan
  • Research Site
    Takasago-shi, 676-0812, Japan
  • Research Site
    Takasaki-shi, 370-0829, Japan
  • Research Site
    Ueda-shi, 386-8610, Japan
  • Research Site
    Yokohama-shi, 231-8682, Japan
  • Research Site
    Yokohama-shi, 234-8503, Japan
  • Research Site
    Yokohama-shi, 236-0004, Japan
  • Research Site
    Busan, 49201, Korea, Republic of
  • Research Site
    Gangwon-do, 26426, Korea, Republic of
  • Research Site
    Seongnam-si, 463-707, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Kaunas, 50177, Lithuania
  • Research Site
    Klaipeda, 92231, Lithuania
  • Research Site
    Siauliai, LT-76231, Lithuania
  • Research Site
    Vilnius, 08661, Lithuania
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Gdańsk, 80-382, Poland
  • Research Site
    Katowice, 40-040, Poland
  • Research Site
    Lublin, 20-709, Poland
  • Research Site
    Ostrowiec Świętokrzyski, 27-400, Poland

Showing the first 100 of 156 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Sep 2023, 31 months.

Results were first posted in Nov 2024, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 20, 2020
StartActual
Jan 26, 2021
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Results first posted
Nov 19, 2024
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04595370
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 20, 2020
Start date
Jan 26, 2021
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Results posted
Nov 19, 2024
Last update
Nov 19, 2024

Study contacts

John McMurray
principal investigator · University of Glasgow, United Kingdom

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion